<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Oncogenic Allele Signature Predicts CRC Cetuximab Response

Cetuximab is an approved standard of care agent for EGFR+ metastatic colorectal cancer (mCRC), excluding patients with KRAS codon 12/13 mutations. However, only 35-50% of patients with wild type KRAS benefit from cetuximab use, and retrospective analyses have shown that patients with KRAS G13D mutation could still benefit from treatment.